Sprint Bioscience AB (publ) (STO:SPRINT)

Market Cap	157.75M
Revenue (ttm)	50.03M
Net Income (ttm)	-25.65M
Shares Out	105.52M
EPS (ttm)	-0.31
PE Ratio	n/a
Forward PE	14.95
Dividend	n/a
Ex-Dividend Date	n/a

Volume	154,654
Average Volume	253,546
Open	1.470
Previous Close	1.495
Day's Range	1.435 - 1.505
52-Week Range	0.360 - 1.820
Beta	-0.78
RSI	56.56
Earnings Date	Feb 12, 2026

About Sprint Bioscience AB

Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 29
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: SPRINT

Financial Performance

In 2024, Sprint Bioscience AB's revenue was 66.14 million, an increase of 27.97% compared to the previous year's 51.69 million. Losses were -18.28 million, 4072.8% more than in 2023.